Sameer Kadri-rodriguez MD, MS

Dr. Sameer S. Kadri is currently an associate research physician and head of the Clinical Epidemiology Section in the Clinical Center's Critical Care Medicine Department.

Dr. Kadri earned his degree in Medicine from the Seth G. S. Medical College and King Edward Memorial Hospital in Mumbai, India. He trained in Internal Medicine at the New York-Presbyterian/Weill Cornell Medical Center, Infectious Diseases at the Massachusetts General Hospital, in Critical Care at the NIH Clinical Center, and in Clinical Epidemiology at the Harvard T.H. Chan School of Public Health.

Dr. Kadri was appointed as Staff Clinician in 2014 and more recently to Tenure Track Investigator in 2021 in the NIH Clinical Center’s Critical Care Medicine Department at the NIH Clinical Center. In this role, he splits his time between attending in the ICU, serving as an NIH principal investigator, supervising a data Lab, and training fellows.

His primary research interest lies in infections in the critically ill. He has leveraged large datasets for epidemiologic outcomes and comparative effectiveness investigations on antimicrobial resistance and sepsis, and more recently, COVID-19 to inform clinical care and health policy.

Since the Pandemic took hold in the U.S., Dr. Kadri’s lab has contributed several landmark investigations to the evidence base, including studies showcasing the detrimental impact of the strain of hospital COVID-19 caseload surges on outcomes, the reliability of diagnosis coding for COVID-19, the risk of reinfection from COVID-19 and the risk factors for severe outcome in vaccine breakthrough infections. He serves as a clinical advisor and collaborator on several CDC-initiated large database studies on COVID-19.

He founded and leads the NIH Antimicrobial Resistance Outcomes Research Initiative (NIH–ARORI), a collaboration between the NIH Clinical Center, Intramural NIAID, the CDC, and Harvard. He developed and tested a novel classification scheme for antimicrobial resistance called “Difficult-to-treat Resistance” or DTR that focuses on non-susceptibility to all first-line antibiotics. His group has performed studies comparing the real-world effectiveness of antibiotics used to treat infections for which clinical trials and unfeasible and unlikely. Hi, lab collaborates closely with other federal agencies and several University-based investigators. Dr. Kadri has been awarded intramural and non-NIH grant funding and has won NIH CEO awards and other accolades from professional societies for his work.

Dr. Kadri has authored over 75 peer-reviewed publications and has served as a peer reviewer and held various editorial positions over the years. He has also spearheaded investigations that underscore the benefits of dual training in critical care medicine and infectious diseases. He is a fellow of the IDSA and serves on the society’s sepsis task force as well as on a CMS technical expert panel for developing an electronic performance measure for sepsis.